Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Reimportation

- PMLiVE

White House unveils plans to reimport medicines from Canada

Unthinkable to previous administrations, but scepticism rife amid flurry of policy ideas

- PMLiVE

PhRMA opposed to Senate drug price control plans

But has bipartisan support and Trump backing

- PMLiVE

Another setback on pricing as Trump drops rebate plans

Follows pharma's blocking of advertising changes

- PMLiVE

Trump presses on with reference pricing plan for medicines

Proposed pilot programme to run until 2025

- PMLiVE

Sanofi joins Lilly in insulin price cut, but lawmakers have lost patience

Insulin price nearly tripled between 2002 and 2013

- PMLiVE

Tit for tat as PBMs blame pharma for high drug prices

US Senate turns its spotlight on 'middlemen'

- PMLiVE

Trump budget targets rebates, out-of-pocket costs

Biotech sector welcomes end to rebates, but worries about Medicare cuts

- PMLiVE

Senate grilling makes pharma CEOs squirm, but give little ground

Some signal willingness to compromise, but oppose most radical reforms

- PMLiVE

CEOs agree to Congressional grilling on US drug prices

Tough questions await pharma bosses

- PMLiVE

End to middlemen rebates a major shift in US drug pricing

Puts onus on pharma, which cites rebates as biggest barrier

- PMLiVE

Merck & Co joins big pharma pricing pledge – but sceptics unconvinced

Large portfolios gives companies room for manoeuvre

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links